FreseniusKabi Oncology is trading lower by 3% at Rs 102 after the pharmaceutical company said it has received a warning letter from the US health regulator asking for certain other information and implementation of more corrective and preventive measures regarding GMP non- conformities.
"The company has received a warning letter from US Food and Drug Administration (USFDA), inter-alia, asking for certain other information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations," Fresenius Kabi Oncology said in a BSE filing.
On February 26, during a routine inspection at the company's API plant located at Kalyani, West Bengal, USFDA had made observations relating to GMP non-conformities in respect of manufacturing, documentation practises and product testing, it added.
The stock opened at Rs 109 and hit a low of Rs 102 on BSE. A combined around 8,000 shares have changed hands on the counter in early morning deals on BSE and NSE.
"The company has received a warning letter from US Food and Drug Administration (USFDA), inter-alia, asking for certain other information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations," Fresenius Kabi Oncology said in a BSE filing.
On February 26, during a routine inspection at the company's API plant located at Kalyani, West Bengal, USFDA had made observations relating to GMP non-conformities in respect of manufacturing, documentation practises and product testing, it added.
The stock opened at Rs 109 and hit a low of Rs 102 on BSE. A combined around 8,000 shares have changed hands on the counter in early morning deals on BSE and NSE.